SUPERNUS PHARMACEUTICALS, INC. Payments of Stock Issuance Costs
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Payments of Stock Issuance Costs of $869.00 thousand for the 12-month period ending 2013-12-31, per its 10-K/A filed 2017-01-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2017-01-20
- SUPERNUS PHARMACEUTICALS, INC. payments of stock issuance costs for fiscal 2013 was $869.00K.
| Period end | Payments of Stock Issuance Costs 12 month |
|---|---|
| 2013-12-31 | $869.00K 10-K/A · filed 2017-01-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |